研究单位：[1]Boehringer Ingelheim[2]Tongji Hospital, Tongji University Wuhan, China, 430030[3]Renmin Hospital of Wuhan University Wuhan, China, 430060[4]First Affiliated Hospital of Xi'an JiaoTong University Xi'an, China, 710061[5]Yanbian University Hospital Yanji, China, 133000[6]the first people hospital of Yue Yang Yueyang, China, 414000[7]Affiliated Hospital of Jiangsu University Zhenjiang, China, 212013[8]Corazon IPS S.A.S. Barranquilla, Colombia, 080003[9]Centro de Reumatologia y Ortopedia SAS, Barranquilla Barranquilla, Colombia, 080020[10]IPS Centro Cientifico Asistencia Barranquilla, Colombia, 080020[11]CardioColombia S.A.S. Bogota D.C, Colombia, 111611[12]Endocare Research Institute Bogota, Colombia, 111611[13]IPS Centro Medico Julián Coronel S.A. Cali, Colombia, 760002[14]Fundación Valle del Lili Cali, Colombia, 760032[15]Poliklinika Humanitas Bilovec, Czechia, 74301[16]Internal and Cardiology Practice, MUDr. Karel Kamenik, Brno Brno, Czechia, 603 00[17]MUDr. Alexandra Ludkova Brno, Czechia, 615 00[18]University Hospital Brno Brno, Czechia, 625 00[19]Vojenska nemocnice Brno Brno, Czechia, 63600[20]Nemocnice Milosrdnych bratri Brno, Czechia, 63900[21]Fakultni nemocnice u sv. Anny v Brne Brno, Czechia, 656 91
研究目的：
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition. The purpose of the study is to find out whether a medicine called empagliflozin lowers the chances of patients having to go to hospital for heart failure and whether it improves their survival. The study is open to patients with a type of chronic heart failure called chronic heart failure with preserved ejection fraction.
Participants stay in the study until researchers have enough information about how effective empagliflozin is. It is expected that participants who enter at the very beginning of the enrolment period may be in the study for over 3 years, while participants who enter near the end of the enrolment period may be in the study for less than 2 years. The participants are put into 2 groups. It is decided by chance who gets into which group. One group gets empagliflozin tablets every day and the other group gets placebo tablets every day. Placebo tablets look like empagliflozin tablets but contain no medicine.
